The authors assumed that:
patients achieved a 35% LDL reduction from baseline after 12 weeks of treatment;
patients would receive one week of free drug samples to determine tolerability;
compliance rates were identical between groups;
outpatient monitoring of plasma calcium and phosphorus concentrations was performed at least four times a year;
liver function tests were performed at baseline, four weeks, three months and six months after starting atorvastatin therapy.